Dogwood Therapeutics (DWTX) Stock Price, News & Analysis

Company Overview

Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Innovative Med Concepts, LLC and changed its name to Virios Therapeutics, Inc. in July 2020. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Key Stats

• Today's Range: $2.09 to $2.85
• 50-Day Range: N/A
• 52-Week Range: $1.62 to $23.50
• Volume: 123,649 shs
• Average Volume: 55,047 shs
• Market Capitalization: $3.63 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DWTX Stock Analysis - Frequently Asked Questions

How have DWTX shares performed this year?

Dogwood Therapeutics' stock was trading at $4.1199 on January 1st, 2024. Since then, DWTX stock has decreased by 33.5% and is now trading at $2.74.
View the best growth stocks for 2024 here.

When did Dogwood Therapeutics' stock split?

Dogwood Therapeutics shares reverse split on Wednesday, October 9th 2024. The 1-25 reverse split was announced on Saturday, January 1st 2000. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

How do I buy shares of Dogwood Therapeutics?

Shares of DWTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Today: 11/21/2024
• Fiscal Year End: 12/31/2024
• Next Earnings (Estimated): 3/06/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:DWTX
• CUSIP: N/A
• CIK: 1818844
• Web: www.dwtx.com
• Phone: (866) 620-8655
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($6.55)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-5,300,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -217.12%
• Return on Assets: -172.06%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.71
• Quick Ratio: 1.71

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.71 per share
• Price / Book: 3.86

Miscellaneous

• Outstanding Shares: 1,330,000
• Free Float: 1,169,000
• Market Cap: $3.64 million
• Optionable: N/A
• Beta: 1.57